Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571940 | 0.88 | RAB9A (0.68) | RAB9AGAAHTTTP53SMN1; SMN2 | |
| SCHEMBL3675929 | 0.85 | TP53 (0.86) | RAB9AGAAHTTTP53SMN1; SMN2 | |
| SCHEMBL12189605 | 0.85 | SMN1; SMN2 (0.62) | RAB9AGAAHTTTP53SMN1; SMN2 | |
| SCHEMBL3827286 | 0.82 | HDAC1 (0.72) | RAB9ATP53SMN1; SMN2NPC1CASP3 | |
| SCHEMBL20476334 | 0.81 | SMN1; SMN2 (0.71) | RAB9AGAAHTTTP53SMN1; SMN2 | |
| SCHEMBL17664561 | 0.81 | RAB9A (0.71) | RAB9AGAAHTTTP53SMN1; SMN2 | |
| SCHEMBL13814818 | 0.81 | NR1H4 (0.58) | RAB9AGAAHTTTP53SMN1; SMN2 | |
| SCHEMBL3670066 | 0.80 | SMN1; SMN2 (0.72) | RAB9AGAATP53SMN1; SMN2NPC1 | |
| SCHEMBL840495 | 0.80 | PTPN1 (0.67) | RAB9AHTTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL12189683 | 0.80 | PTPN1 (0.67) | RAB9ATP53SMN1; SMN2NPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | RAB9A 2737/4885GAA 4725/4885HTT 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.